Cenegermin
Orphan Drug Cold Chain RequiredFDA Approved
Description
Cenegermin is a recombinant human nerve growth factor (rhNGF) used to treat neurotrophic keratitis. It promotes corneal healing.
Indications & Therapeutic Use
Neurotrophic keratitis
Global Availability (4 countries)
| Country | Access Route | Regulatory Pathway | Lead Time | Status |
|---|---|---|---|---|
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — |
Available Through
This drug is available for procurement through the following fulfilment partner.
Fulfilment Partner
Cenegermin
| Generic Name | Cenegermin |
| Brands | 1 brand available |
| Active Ingredient | Cenegermin-bkbj |
| Drug Class | Neurotrophic keratitis |
| Manufacturer | Dompé farmaceutici S.p.A. |
| Dosage Forms | Ophthalmic solution |
| Medical Code | S01XA24 |
| Orphan Status | Yes — Orphan Drug |
| Cold Chain | Required |
| Lead Time | 21 days |
| Reg. Status | FDA Approved |
| Clinical Trial | NCT02648350 |
| Countries | 4 countries |
Authority Signals
Last Verified3/21/2026
Data ConfidenceHigh (AI + Pharmacist)
Source Citations5 Validated Nodes